{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.28","value":"1.5"},{"groupId":"OG001","spread":"0.28","value":"0.4"},{"groupId":"OG002","spread":"0.28","value":"0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"332"},{"groupId":"OG002","value":"320"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.29","value":"1.6"},{"groupId":"OG001","spread":"0.29","value":"0.9"},{"groupId":"OG002","spread":"0.29","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"},{"groupId":"OG001","value":"312"},{"groupId":"OG002","value":"301"}],"units":"Participants"}],"title":"Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.29","value":"2.3"},{"groupId":"OG001","spread":"0.29","value":"1.8"},{"groupId":"OG002","spread":"0.29","value":"2.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"301"},{"groupId":"OG002","value":"287"}],"units":"Participants"}],"title":"Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.29","value":"3.3"},{"groupId":"OG001","spread":"0.29","value":"3.8"},{"groupId":"OG002","spread":"0.29","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"291"},{"groupId":"OG001","value":"290"},{"groupId":"OG002","value":"277"}],"units":"Participants"}],"title":"Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.29","value":"3.5"},{"groupId":"OG001","spread":"0.28","value":"4.0"},{"groupId":"OG002","spread":"0.29","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"249"}],"units":"Participants"}],"title":"Cycle 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.30","value":"3.8"},{"groupId":"OG001","spread":"0.30","value":"4.0"},{"groupId":"OG002","spread":"0.30","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"254"},{"groupId":"OG001","value":"254"},{"groupId":"OG002","value":"225"}],"units":"Participants"}],"title":"Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.30","value":"4.2"},{"groupId":"OG001","spread":"0.30","value":"3.8"},{"groupId":"OG002","spread":"0.30","value":"3.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"226"},{"groupId":"OG002","value":"207"}],"units":"Participants"}],"title":"Cycle 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.32","value":"4.1"},{"groupId":"OG001","spread":"0.32","value":"3.7"},{"groupId":"OG002","spread":"0.32","value":"3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"203"},{"groupId":"OG002","value":"202"}],"units":"Participants"}],"title":"Cycle 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.32","value":"4.4"},{"groupId":"OG001","spread":"0.32","value":"4.0"},{"groupId":"OG002","spread":"0.32","value":"3.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"171"},{"groupId":"OG002","value":"178"}],"units":"Participants"}],"title":"Cycle 19"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.34","value":"4.3"},{"groupId":"OG001","spread":"0.34","value":"3.6"},{"groupId":"OG002","spread":"0.33","value":"3.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"174"}],"units":"Participants"}],"title":"Cycle 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.33","value":"4.0"},{"groupId":"OG001","spread":"0.33","value":"3.9"},{"groupId":"OG002","spread":"0.32","value":"3.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"154"}],"units":"Participants"}],"title":"Cycle 23"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.34","value":"4.0"},{"groupId":"OG001","spread":"0.35","value":"4.1"},{"groupId":"OG002","spread":"0.33","value":"3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"127"},{"groupId":"OG002","value":"145"}],"units":"Participants"}],"title":"Cycle 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.33","value":"4.4"},{"groupId":"OG001","spread":"0.34","value":"4.2"},{"groupId":"OG002","spread":"0.32","value":"3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"120"},{"groupId":"OG002","value":"130"}],"units":"Participants"}],"title":"Cycle 27"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.34","value":"4.4"},{"groupId":"OG001","spread":"0.35","value":"4.4"},{"groupId":"OG002","spread":"0.33","value":"3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"114"},{"groupId":"OG002","value":"136"}],"units":"Participants"}],"title":"Cycle 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.36","value":"4.0"},{"groupId":"OG001","spread":"0.37","value":"4.2"},{"groupId":"OG002","spread":"0.35","value":"3.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"109"},{"groupId":"OG002","value":"120"}],"units":"Participants"}],"title":"Cycle 31"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.38","value":"4.1"},{"groupId":"OG001","spread":"0.38","value":"4.4"},{"groupId":"OG002","spread":"0.36","value":"3.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"105"},{"groupId":"OG002","value":"123"}],"units":"Participants"}],"title":"Cycle 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.37","value":"4.4"},{"groupId":"OG001","spread":"0.37","value":"4.2"},{"groupId":"OG002","spread":"0.35","value":"3.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"111"}],"units":"Participants"}],"title":"Cycle 35"}],"denoms":[{"counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"383"},{"groupId":"OG002","value":"382"}],"units":"Participants"}],"description":"The Disease Related Symptom score is a subset of the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), which evaluates nine symptoms related to ovarian cancer. The NFOSI-18 DRS score ranges from 0 to 36, with higher scores indicating a lower burden of symptoms and a score of 0 being severely symptomatic. A 3-point difference was defined as clinically meaningful. A positive change from Baseline indicates improvement.\n\nChange from Baseline was calculated using a used a mixed-model for repeated measures (MMRM) with treatment, stratification factors of residual disease, stage of disease, choice of paclitaxel dosing regimen and BRCA-deficient status, time point and treatment-by-time point interaction as fixed effect factors, and Baseline DRS score as a covariate.\n\nDRS was not included in the fixed-sequence testing procedure.","dispersionType":"Standard Error","groups":[{"description":"Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve \\[AUC\\] of 6 mg per milliliter per minute (mg/mL/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.","id":"OG000","title":"Placebo + Carboplatin + Paclitaxel -> Placebo"},{"description":"Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.","id":"OG001","title":"Veliparib + Carboplatin + Paclitaxel -> Placebo"},{"description":"Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.","id":"OG002","title":"Veliparib + Carboplatin + Paclitaxel -> Veliparib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized participants with available data at each time point","reportingStatus":"POSTED","timeFrame":"Baseline and Day 1 of Cycles 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35","title":"Change From Baseline in Disease Related Symptom (DRS) Score in the Whole Population","type":"SECONDARY","unitOfMeasure":"score on a scale"}